Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
As a result of increasing obesity, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease. Non-alcoholic steatohepatitis (NASH) is the pathogenic form of NAFLD and can progress to cirrhosis and need for liver transplantation. There is currently no Health Canada-approved therapy for the treatment of NASH. The intestinal microbiome has been shown to contribute to the development of NASH. This project aims to understand the impact of alterations in the intestinal microbiome on the development and progression of NASH development, and how probiotics (Lacidofil, Lallemand health solutions Inc.) can inhibit progression to significant scarring of the liver. These results will help to expand the current knowledge on probiotics as a preventive and therapeutic option for NASH.
Lallemand Health Solutions
University of Toronto
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.